Skip to main content

Table 1 Interaction analyses for individual KIR and KIR ligand genotypes with TTRF

From: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

    TTRF
Line Treatment Genotype Group Number of Events/n 4 yr Fail Rate (95% CI)a % Interaction p-value
1 Maintenance KIR2DL1+/C2+ 21/52 38 (25–54) 0.524
2 Maintenance not KIR2DL1+/C2+ 7/28 30 (15–56)
3 Non-Maintenance KIR2DL1+/C2+ 18/49 38 (26–55)
4 Non-Maintenance not KIR2DL1+/C2+ 6/30 21 (9–43)
5 Maintenance KIR2DL2+/C1+ 11/36 32 (18–53) 0.547
6 Maintenance not KIR2DL2+/C1+ 17/44 38 (25–56)
7 Non-Maintenance KIR2DL2+/C1+ 6/28 24 (10–49)
8 Non-Maintenance not KIR2DL2+/C1+ 18/51 36 (24–52)
9 Maintenance KIR2DL3+/C2+ 17/56 33 (21–50) 0.982
10 Maintenance not KIR2DL3+/C2+ 11/24 41 (23–64)
11 Non-Maintenance KIR2DL3+/C2+ 16/60 27 (17–43)
12 Non-Maintenance not KIR2DL3+/C2+ 8/19 45 (25–70)
13 Maintenance KIR3DL1+/Bw4+ 20/54 38 (25–55) 0.055
14 Maintenance not KIR3DL1+/Bw4+ 8/26 29 (15–52)
15 Non-Maintenance KIR3DL1+/Bw4+ 13/50 25 (15–41)
16 Non-Maintenance not KIR3DL1+/Bw4+ 11/29 43 (25–66)
  1. a95% Confidence interval; lines 13-14 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome